Research with rigorous science and ambitious goals
Life sciences are radically improving the chances of treatment - even for diseases that have yet to find therapeutic answers. We believe that with new knowledge of biotechnology, combined with ever-increasing computing power and the advancement of artificial intelligence, the pace towards effective treatment is increasing.
At Dompé, our attention remains focused on rare diseases - often untreated – and on therapeutic needs - still unmet - in areas such as ophthalmology, diabetes, oncology, and organ transplants. The research team’s efforts have been rewarded as the approval of our first drug for a rare disease. Gaetano D’Anniballe, Biotech R&d Director at Dompé farmaceutici, explains its development
Our research results are published in international journals.
DISCOVERY AND EARLY DEVELOPMENT PLATFORM
Our platform spans all development phases of new synthetic molecules, mainly targeting G protein-coupled receptors (GPCR) and ion channels. These include the rational design of new clinical classes, the selection of the most promising active ingredients for which characterization should be started in order to identify new therapies to develop, register, and market.
The integration of the Design and Discovery Platform and Early Clinical Development Platform systems allows us to develop a wide pipeline encompassing the pre-clinical and more advanced phases.
We use next-generation proprietary chemo- and bioinformatic tools, including the Exscalate platform.
Our biotech platform provides a set of innovative application responses - from gene cloning to the expression of the protein encoded by it from its purification and characterization - to its laboratory-scale and industrial-scale production - to the GMP release of the drug substance
The platform is equipped with state-of-the-art tools, such as:
- a plant with a fermentation capacity between 30 and 300 liters;
- a GMP unit for low temperature storage (-70°C and -160°C) of cell banks;
- a state-of-the-art system for purifying, characterizing and releasing the active protein ingredients for clinical studies and commercial use.
Our biotech platform also provides CDMO (Contract Development and Manufacturing Organization) activities for third parties - from small to Big Pharma companies-and is certified by international supervisory bodies.
Our Technology R&D laboratories study and develop new formulations (materials, vehicles and excipients) and new administration methods for:
- novel small molecules, biological compounds and active ingredients
- existing products, to streamline their life cycle management
Our state-of-the-art equipment allows for a full characterization and analysis of chemical-physical interactions between the drug and the delivery system.
Our Research and Development activities are conducted as part of an international network.
We operate in an ‘open innovation’ environment based on a network of over 300 research centers and universities in Italy and across the world: an evolving scientific ecosystem that helps us develop and share innovation.
These activities result in a number of publications in scientific journals and international patents worldwide.espacenet.com.